261
Participants
Start Date
April 12, 2019
Primary Completion Date
March 16, 2020
Study Completion Date
November 25, 2020
Erenumab
Administered by subcutaneous injection once a month
Placebo
Administered by subcutaneous injection once a month
Research Site, Matsuyama
Research Site, Kasuga-shi
Research Site, Kasuga-shi
Research Site, Hiroshima
Research Site, Hiroshima
Research Site, Sapporo
Research Site, Sapporo
Research Site, Sapporo
Research Site, Kobe
Research Site, Kahoku-gun
Research Site, Morioka
Research Site, Takamatsu
Research Site, Kagoshima
Research Site, Kawasaki-shi
Research Site, Kawasaki-shi
Research Site, Kochi
Research Site, Kumamoto
Research Site, Kumamoto
Research Site, Kyoto
Research Site, Sendai
Research Site, Ōita
Research Site, Osaka
Research Site, Toyonaka-shi
Research Site, Saga
Research Site, Iruma-gun
Research Site, Saitama-shi
Research Site, Tokorozawa-shi
Research Site, Shizuoka
Research Site, Shimotsuga-gun
Research Site, Chofu-shi
Research Site, Hachioji-shi
Research Site, Minato-ku
Research Site, Minato-ku
Research Site, Shibuya-ku
Research Site, Shinjuku-ku
Research Site, Tottori-shi
Research Site, Yonago-shi
Research Site, Toyama
Research Site, Hofu-shi
Research Site, Yamaguchi
Research Site, Kai-shi
Lead Sponsor
Amgen
INDUSTRY